Stoic VC

Kinoxis Therapeutics is an early-stage Australian biotechnology company focused on developing novel therapeutics for substance use disorders and other central nervous system conditions. It licenses its compounds from the University of Sydney. Its lead candidate has shown potent anti-addictive and prosocial effects in multiple animal models and is advancing through preclinical testing. The company is also developing KNX100, described as a first-in-class treatment for agitation in dementia and substance use disorders through a novel mechanism intended to modulate dysregulated brain systems and provide safe, effective therapy.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Founded in 2016, Wildlife Drones specializes in designing and developing innovative animal radio-tracking systems using drones. With over two decades of experience in ecological research, the company understands the challenges in tracking highly mobile animals and has created a solution that improves signal detection and reduces labor intensity.

OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.

Morse Micro is a wireless semiconductor company developing low-power Wi-Fi HaLow chips for the Internet of Things. Built by Wi‑Fi pioneers and industry veterans, the company focuses on long-range, energy-efficient connectivity across IoT applications such as surveillance, access control, industrial automation, and mobile devices. Its IP and patents support the design of its chips. Headquartered in Australia with offices in China and the United States, Morse Micro aims to deliver affordable, scalable IoT connectivity for a wide range of devices.

Agerris Pty Ltd, established in 2005 and based in Chippendale, Australia, specializes in designing and manufacturing modular robotics for the agricultural industry. The company's flagship product, Swagbot, is a modular robot that autonomously monitors and addresses weed issues, detects food, herds livestock, and assesses crops using computer vision. Additionally, Agerris develops an AI-based platform, Digital Farmhand, which enables farm machinery to detect and assess weeds, count individual fruit, nuts, crops, and animals. The company's products cater to various applications, including tree crop and row crop automation, intelligent spraying, livestock monitoring, and fruit and crop detection.

Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation, intercom capabilities, and active noise-cancelling technology. Recognizing the inherent dangers of motorcycling, Forcite aims to significantly improve safety for riders by integrating sensor technology and a proprietary software platform called Forcite Command. By utilizing lightweight carbon fiber in their helmet designs, the company seeks to provide a disruptive solution that addresses the lack of standard safety equipment in motorcycles, ultimately making riding safer and more enjoyable.

Q-Sera develops innovative blood collection tubes using synthetically produced snake venom-derived pro-coagulant proteins. These tubes accelerate blood clotting, rapidly producing high-quality serum for biochemical analysis, thereby enhancing laboratory efficiency and patient care.

Kinoxis Therapeutics is an early-stage Australian biotechnology company focused on developing novel therapeutics for substance use disorders and other central nervous system conditions. It licenses its compounds from the University of Sydney. Its lead candidate has shown potent anti-addictive and prosocial effects in multiple animal models and is advancing through preclinical testing. The company is also developing KNX100, described as a first-in-class treatment for agitation in dementia and substance use disorders through a novel mechanism intended to modulate dysregulated brain systems and provide safe, effective therapy.

Kinoxis Therapeutics is an early-stage Australian biotechnology company focused on developing novel therapeutics for substance use disorders and other central nervous system conditions. It licenses its compounds from the University of Sydney. Its lead candidate has shown potent anti-addictive and prosocial effects in multiple animal models and is advancing through preclinical testing. The company is also developing KNX100, described as a first-in-class treatment for agitation in dementia and substance use disorders through a novel mechanism intended to modulate dysregulated brain systems and provide safe, effective therapy.

Cardihab Pty Ltd., established in 2016 and based in Fortitude Valley, Australia, specializes in digital cardiac rehabilitation solutions. It offers a cloud-based portal and smartphone app, enabling clinicians to manage patient data, track goals, and connect to sensors. This allows for remote cardiac rehabilitation, reducing the need for frequent clinic visits and making the process more convenient and flexible for patients.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.